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Context: Salivary testosterone (Sal-T) measurement by LC-MS/MS resents the opportunity to ex-
amine health correlates of Sal-T in a large-scale population survey.
Objective: To examine associations between Sal-T and health-related factors in men and women
aged 18–74 years.
Design & Setting: Morning saliva samples were obtained from participants in a cross-sectional
probability-sample survey of the general British population (‘Natsal-3). Self-reported health and
lifestyle questions were administered as part of a wider sexual health interview.
Participants: 1,599 men; 2,123 women.
Methods: Sal-T wasmeasured using LC-MS/MS; linear regressionwas used to examine associations
between health factors and mean Sal-T.
Results: In men, mean Sal-T was associated with a range of health factors after age-adjustment,
showing a strong independent negative association with BMI. Men reporting cardiovascular dis-
ease or currently taking medication for depression had lower age-adjusted Sal-T, although there
was no association with cardiovascular disease after adjustment for BMI. The decline in Sal-T with
increasingage remainedafteradjustment forhealth-related factors. Inwomen, Sal-Tdeclinedwith
increasing age, however there were no age-independent associations with health-related factors
or specific heath conditions, with the exception of higher Sal-T in smokers.
Conclusions: Sal-T levels were associated, independently of age, with a range of self-reported
healthmarkers, particularly BMI, inmen but not women. The findings support the view that there
is an age-related decline in Sal-T in men and women, which cannot be explained by an increase in
ill-health. Our results demonstrate the potential of Sal-T as a convenient measure of tissue an-
drogen exposure for population research.
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In men, testosterone deficiency with pituitary or testicu-lar disease (male hypogonadism) is known to cause a
wide range of symptoms and conditions including sexual
dysfunction, loss of vigour, poor physical performance,
fractures, and low mood, which can be effectively treated
withTestosteroneReplacementTherapy (TRT) (1).How-
ever, the more general relationship between male testos-
terone levels and ill-health is less well understood. Com-
munity-based studies in men have shown associations
between lower average serum testosterone (serum-T) and
poorer health outcomes, including frailty, obesity, insulin
resistance, cardiovascular diseases and mortality, al-
though findings have not always been consistent (2–5). It
is suggested that lower testosterone levels in older men
may contribute to these ageing-related conditions al-
though questions remain about direction and causality
(3). Some studies have also cast doubt as to whether there
truly is an independent age-related decrease in testoster-
one, or whether the observed decline is a biomarker of
accumulated comorbidities (6). Currently, whether tes-
tosterone treatmentwouldbenefit symptomatic oldermen
with low testosterone remains a subject of intense debate
and research (7, 8).Many of the existing studies have been
carried out in middle-aged or older men, and the health
implications of lower testosterone in younger men are un-
clear. In women, circulating concentrations of testoster-
one are typically around 5%–10% of those in men, with
distinct age-related declines, independent of the meno-
pause (9, 10). The evidence for associations between tes-
tosterone and health in women is even more equivocal
than for men (10–13). Furthermore, research efforts in
women have been seriously hampered by inadequate sen-
sitivity of serum-T measurements, due to the low concen-
tration of testosterone and poor specificity of commonly-
used immunoassay methods (14).
Salivary testosterone (Sal-T) is believed to represent tis-
sue hormone levels which are unaffected by variations in
circulating binding proteins (15) thereby providing an al-
ternative to serum free testosterone (free-T) in the assess-
ment of androgen status. In contrast to the collection of
serum,which is invasive andexpensive, collectionof saliva
is relatively straightforward and requires minimal train-
ing. We have recently demonstrated that Sal-T can be re-
liably and accurately measured by a highly sensitive and
specific liquid chromatography tandem mass spectrome-
try (LC-MS/MS) method (16). In a validation study com-
paring samples from the same individuals, we found that
Sal-T in adult men and women correlated more strongly
with calculated serum free-T than serum total-T (17) and
was also unaffected by variations in SHBG (18). Fiers at al
confirmed the good correlation in both men and women
between Sal-T and serum free-T measured by equilibrium
dialysis but therewas a significant systematic positive bias
inwomen, whichmay reflect the influence of salivary pro-
tein binding on the lower female concentrations of Sal-T
(19). We have described the age-specific distribution of
Sal-T in British men aged 18–69 years and women aged
18–74 years (20). However, the physiological and health-
related behavioral correlates of Sal-T have not yet been
explored.
Using data from the third National Survey of Sexual
Attitudes and Lifestyles (Natsal-3), a probability-sample
survey of British men and women, we investigated
whether Sal-T is associated, independently of age, with
demographic characteristics, lifestyle, general health, and
reported health conditions. We hypothesized that rela-
tionships between Sal-T and health-related factors in men
would be similar to those previously observed with serum
free-T. To our knowledge, this is the first study to have
examined the associations between Sal-T and health in a
large community sample ofmenandwomenusing ahighly
sensitive and specific assay, exploiting the theoretical and
practical advantages of salivary measurements to the full.
Materials and Methods
Participants and procedures
Full details of the Natsal-3 methods, including details of the
saliva sample collection and testing, are described elsewhere
(20–22). Briefly, Natsal-3 was a probability-sample survey of
15 162 men and women aged 16–74 years resident in Britain.
Interviews tookplacebetweenSeptember2010andAugust 2012
using a combination of computer-assisted personal interviewing
(CAPI) and computer-assisted self-interview (CASI) for themore
sensitive questions. The response rate was 57.7%.
Single morning saliva samples were self-collected from a sub-
sample of men and women aged 18–74 years, who did not reg-
ularly work night shifts. Consenting participants were given a
self-collection pack and asked to provide their sample before
10am, to minimize diurnal variation in T (7). They were asked
not tobrush their teeth, eat or chewbefore giving the sample, and
to spit directly into a plain polystyrene tube. Saliva samples were
posted to the laboratory where they were prepared and frozen at
–80°Cuntil analysis.On receipt of the sample, participantswere
sent a £5 voucher as a token of appreciation. Altogether, 9170
eligible participants were invited to provide a saliva sample:
6515 (71.0%) agreed to do so and 4591 samples were received
by the laboratory and matched to the survey data (50.1% of
those invited). A total of 463 samples were excluded due to sam-
ple quality issues (20) (insufficient volume (n  154); sample
discoloured/bloody (n  91); sample recorded as taken after
10.30am (n  34); period between sample being taken and re-
ceived by the laboratory more than 5 days or unknown due to
missing date of collection (n 172); not tested due to error (n
12)) leaving 4128 participants (45.0% of those invited) with a
testosterone result (1,675 men; 2453 women). This paper ex-
amines associations between Sal-T andhealth in the general pop-
ulation, therefore 76 men and 330 women with clinical condi-
2 Salivary testosterone and health in British men and women J Clin Endocrinol Metab
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 19 September 2016. at 07:07 For personal use only. No other uses without permission. . All rights reserved.
tionsor takingmedication likely toaffect testosterone levelswere
excluded from analysis (individuals may be excluded for more
than one reason): currently taking medication for epilepsy (15
men; 15 women) or prostate disease (43 men); treatment for
ovarian, testicular, or pituitary condition (16men; 23women)or
for polycystic ovaries (35 women) in the past year; pregnant at
interview (42women); current receipt of HRT (62women); ever
receipt of HRT together with having had a hysterectomy (proxy
measure for having had ovaries removed; 181 women); missing
data for these questions (3 men; 15 women); resulting in 1599
men and 2123 women being included in the analysis. These ex-
clusions aimed to minimize confounding of the relationship be-
tween testosterone and health caused by these factors which are
known to influence testosterone levels, while retaining an oth-
erwise representative sample of the general population. Women
taking hormonal contraception (oral contraceptive (OC) pill,
mirena, injections, implants, or the contraceptive patch) were
included in analyses in order to allow examination of the rela-
tionship between hormonal contraception and sal-T, and to
avoid biases which may result from excluding this substantial
proportion of women (24% of all women with a valid saliva
sample usually used a hormonal contraception, and this was
67% in the youngest age group (18–24 years)). However, addi-
tional sensitivity analyses were carried out excluding women
takinghormonal contraception, to assesswhether their inclusion
affected associations with health factors.
Measures
Health and medication questions were self-reported, and
bodymass index (BMI) was calculated from self-reported height
and weight. Due to small numbers of underweight individuals
(BMI 18.5), these participants were excluded from analysis of
BMI (14men and 44women).Most of the health questionswere
asked in the CAPI, with the exception of depressive symptoms
(past 2 weeks) whichwere assessed in the CASI using a validated
two-item patient health questionnaire (PHQ-2) (23). Cardiac,
vascular disease, or hypertension were defined as ever being
given such diagnoses by a doctor.
Wepreviously identified seasonal variation in Sal-T, (20) thus
seasonof data collectionwas included as a potential confounder,
defined as: winter (December, January, February), spring
(March,April,May), summer (June, July,August), autumn (Sep-
tember, October, November).
The LC-MS/MS Sal-T assay was developed using strict vali-
dation criteria, (24) with a lower limit of quantification of 6.5
pmol/L. Full details of the laboratory methods, including the
validation of the assay, have been published elsewhere (17, 20).
Statistical analyses
Statistical analyses were carried out using STATA (version
13.1) accounting for the complex survey design (stratification,
clustering, and weighting of the sample) (25). We applied two
weights: the survey weight corrected for unequal probability of
selection anddifferential response (by age, sex, and region) to the
survey itself; the additional saliva weight corrected for unequal
probability of selection and differential response to the saliva
sample. Factors found to be associated with providing a usable
saliva sample included age at interview, ethnicity, self-reported
general health, and sexual function; the saliva weighting signif-
icantly reduced these biases (21).
Descriptive statistics are presented as means (standard er-
rors), with multivariable linear regression used to assess differ-
ences between groups. Throughout, we censored very high Sal-T
values so that, for each10-year age group stratifiedby sex, values
above the 99th percentile were assigned a value equal to that of
the 99th percentile. The Sal-T data for men were normally dis-
tributed, however the distribution for women was positively
skewed and so values were transformed on the natural log scale
for analysis. Accordingly, for men we present linear regression
coefficients representing differences in mean testosterone in
pmol/l, whereas for womenwe present ratios of geometric mean
Sal-T obtained from exponentiated coefficients. Interval regres-
sion was used to assign values to the range 0 to 6.5 pmol/l for 3
men, and 0.5 (to allow log transformation) to 6.5 pmol/l for 62
women with testosterone levels below the limit of detection
(6.5 pmol/l). Age was adjusted for using both linear and qua-
dratic terms to account for a nonlinear relationship of testoster-
onewith age. In our previous presentation of the age distribution
of sal-T, (20) we truncated analyses formen at age 69 aswewere
unable to calculate robust upper (97.5th) and lower (2.5th) per-
centiles based on the standard deviation for older men. Here we
have included data for the full age range ofmen (18–74 years) as
the focus is on differences in mean Sal-T, rather than the 2.5th
and 97.5th percentiles.
As several associations were found for men, multivariable
analyses were used to determine which health factors were in-
dependently associated with Sal-T. Variables were grouped into
a series of domains, in order to identify their individual contri-
butions to the overall relationships with Sal-T after adjustment
for earlier domains. The domains were: 1) age and season; 2)
relationship status and children; 3) BMI and 4) general health. A
fifth lifestyle domain (smoking, alcohol consumption; drug use)
contained no significant associations (either age-adjusted or
multivariable) and was therefore not presented in the final mul-
tivariable table. Within each domain the variables were entered
into a forward stepwise model selection process (significance
level for inclusion P  .1) with variables selected from earlier
domains includedwith certainty.Theorderingof domains began
with factors for which the evidence of association was best es-
tablished (from earlier publications) or of a demographic nature,
and then proceeded to health-related factors. In this way, any
identified associations between Sal-T and health could be seen as
robust and not explained by confounding factors in other do-
mains. An equivalent analysis was not performed for women
given the lackof age-adjusted associations. In further analysiswe
examined associations between specific health conditions or
medical treatments and Sal-T, adjusting firstly for age and then
for those factors that had been cumulatively selected from do-
mains 1 to 3.
Ethics
The Natsal-3 study was approved by the Oxfordshire Re-
search Ethics Committee A (reference: 09/H0604/27). Written
informed consent was obtained for anonymised testing of saliva
samples, without return of results.
Results
Age-adjusted associations of demographic and
general health factors with mean Sal-T (Table 1 &
2, figures 1 & 2)
For both men and women, mean Sal-T decreased with
increasing age, and seasonal variation was observed, as
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Table 1. Sample characteristics, mean salivary Testosterone (Sal-T), and associations between Sal-T and
demographic and health factors: MEN
Denominators
(n) unwt, wt
mean sal-T
(pmol/liter) (SE.)
age-adjusted#
coefficients (95% CI)
All men 1599 1886 223.49 3.33
Age, season, region
Age group P  0.0001
18–24 186 242 315.81 9.14 - -
25–34 245 328 264.62 7.77 51.19 (-74.44, 27.94)
35–44 236 363 234.16 8.42 81.65 (-105.90,
57.41)
45–54 297 388 205.74 5.11 110.08 (-130.78,
89.37)
55–64 330 334 174.63 4.34 141.18 (-160.84,
121.52)
65–74 305 231 151.72 3.74 164.09 (-183.51,
144.68)
Season P  0.0360
winter 400 500 235.15 6.93 - -
spring 464 521 223.77 6.09 5.75 (-20.90, 9.40)
summer 421 457 207.52 6.02 20.73 (-36.74, 4.72)
autumn 314 408 226.74 6.40 2.95 (-19.42, 13.52)
Region P  0.2432
Scotland & North of England 558 639 230.52 5.74 - -
Midlands & Wales 355 391 224.33 6.48 7.20 (-21.22, 6.81)
East of England & South of
England
686 856 217.86 5.17 11.08 (-24.14, 1.99)
Relationship and children
Relationship status P  0.0103
Married / civil partnership /
cohabiting
928 1277 206.71 3.95 - -
Steady relationship, not living
together
187 179 263.63 8.34 14.62 (-1.89, 31.13)
Not in a steady relationship 459 405 261.46 6.97 20.12 (6.41, 33.82)
Any natural children P  0.374
No 642 736 256.27 5.99 - -
Yes 928 1104 204.97 3.62 5.80 (-18.61, 7.00)
Lives with a child (aged
18y)
P  0.7611
No 1281 1342 220.84 3.76 - -
Yes 318 544 230.05 6.18 2.17 (-16.21, 11.86)
BMI
BMI$ P  0.0001
Normal (BMI 18.5–25 kg/m2) 599 723 253.68 5.07 - -
Overweight (BMI 25–30 kg/m2) 612 715 209.82 4.09 23.63 (-34.81, 12.46)
Obese (BMI 30 kg/m2) 334 365 174.34 5.72 51.26 (-64.64, 37.88)
General health and
function
Self-reported general
health
P  0.0054
Very good/good 1253 1510 232.72 3.83 - -
Fair/bad/very bad 346 375 186.37 5.08 16.14 (-27.50, 4.78)
Longstanding illness or
disability
P  0.0131
No 977 1251 238.63 4.15 - -
Yes 621 634 193.69 4.54 13.36 (-23.91, 2.81)
Difficulty walking up stairs
because of a health
problem
P  0.0499
No difficulty 1369 1643 230.41 3.59 - -
Some difficulty 166 177 182.11 7.60 8.31 (-23.34, 6.71)
Much difficulty or unable 64 66 162.09 12.08 23.74 (-44.08, 3.41)
(Continued )
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previously reported (20). Amongmen, therewas variation
in mean sal-T by relationship status after adjustment for
age, with the highest levels among those who were not
currently in a steady relationship, and lowest levels among
thosewhoweremarriedor cohabiting (age-adjusted linear
regression coefficient for those not in a steady relation-
ship, compared with those married/cohabiting: 20.12
(95% confidence interval (CI): 6.41 to 33.82)); no asso-
ciation was found with having children. There were no
associations with demographic factors for women.
Mean Sal-T was associated, independently of age, with
a range of measures of general health in men but not in
women. In age-stratified analyses of men, mean Sal-Twas
seen tobe lowerwith increasingBMI (normal, overweight,
obese) (figure 1), and somewhat higher in those reporting
goodorverygoodhealth (figure2) at least at younger ages;
these associations were not seen in women. Expressed as
age-adjusted regression coefficients, we found levels were
lower among men who were overweight or obese, (coef-
ficients –23.63 (-34.81 to –12.46) and –51.26 (-64.64 to
–37.88) respectively, compared with normal BMI) re-
ported poorer general health (-16.14 (-27.50 to –4.78)),
longstanding illness or disability (-13.36 (-27.50 to
–4.78)); difficulty walking up stairs (-23.74 (-44.08 to
–3.41) for those with much difficulty/inability, compared
with no difficulty), or two or more comorbid health con-
ditions (-21.57 (-35.10 to –8.04) compared with none).
There was no association among men with smoking, al-
cohol consumption or illicit drug use.
The only health association found for womenwaswith
smoking, with higher Sal-T among women who smoked
(ratio of geometric means 1.11 (1.02–1.22) for current
smokers compared with nonsmokers). Women who used
hormonal contraception (HC) as their usual method of
contraception had lowermean Sal-T (Geometric mean ra-
tio compared with those who hadn’t taken HC: 0.78
(0.70–0.87), P .0001). A sensitivity analysis excluding
women on HC (n  499) produced generally similar re-
sults, although the associationwith smoking became non-
significant due to an increase in the size of the confidence
intervals (age-adjustedGeometricmean ratio: 1.08 (0.98–
1.19), P .107). Adjusting the women’s analysis for sea-
son as well as age did not change any of the results (data
not shown).
Multivariable analyses of men (Table 3)
In men, all associations with variables in domains 1–3
in the age-adjusted analyses remained significant in the
multivariable analyses: age, season, relationship status,
and BMI.Only one variable fromdomain 4 - self-reported
general health - was selected in the model, although pro-
viding inconclusive evidence of an association (-11.39
(-22.69 to –0.10) P .048). In further exploratory anal-
ysis we fitted a model excluding BMI but including age,
Table 1. Continued
Denominators
(n) unwt, wt
mean sal-T
(pmol/liter) (SE.)
age-adjusted#
coefficients (95% CI)
Number of comorbid
conditions*
P  0.0073
0 913 1169 245.12 4.38 - -
1 397 435 201.40 5.87 11.10 (-24.18, 1.98)
2 289 282 167.97 5.49 21.57 (-35.10, 8.04)
Lifestyle
Current smoker P  0.6599
No 1247 1458 219.63 3.60 - -
Yes 352 428 236.67 7.20 3.01 (-10.42, 16.45)
Average alcohol
consumption per week
P  0.3611
None 295 343 213.51 7.44 - -
Not more than recommended 1130 1352 226.02 3.98 9.51 (-5.57, 24.59)
More than recommended 167 183 223.35 9.83 14.50 (-7.32, 36.32)
Taken non-prescribed
drugs, past year
P  0.7584
No 1363 1585 218.03 3.52 - -
Yes 197 244 264.34 9.03 2.89 (-15.56, 21.34)
#adjusted for age and age-squared to account for non-linear relationship between testosterone and age
*Measure of comorbidity includes arthritis, heart attack, coronary heart disease, angina, other forms of heart disease, hypertension, stroke,
diabetes, broken hip or pelvis bone or hip replacement ever, backache lasting longer than 3 months, any other muscle or bone disease lasting
longer than 3 months, treatment for depression, treatment for cancer, and treatment for any thyroid condition in the past year.
$Those with BMI18.5 have been excluded from analysis due insufficient numbers to analyse this group separately
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Table 2. Sample characteristics, mean salivary Testosterone (Sal-T), and associations between Sal-T and
demographic and health factors: WOMEN
Denominators
(n) (unwt, wt)
mean sal-T
(pmol/liter) (SE.)
age-
adjusted
Ratios# (95% CI)
All 2123 1899 37.09 0.86
Age, season, region
Age group P  0.0001
18–24 231 252 49.98 4.15 - -
25–34 390 359 41.74 1.82 0.93 (0.78, 1.12)
35–44 391 381 40.49 1.92 0.91 (0.76, 1.09)
45–54 408 390 34.16 1.55 0.76 (0.63, 0.91)
55–64 378 304 27.35 0.98 0.63 (0.53, 0.75)
65–74 325 213 27.24 1.25 0.60 (0.50, 0.72)
Season P  0.0001
winter 529 460 31.57 1.09 - -
spring 652 556 37.71 1.95 1.15 (1.05, 1.26)
summer 491 394 42.46 1.83 1.28 (1.16, 1.40)
autumn 451 489 37.27 1.65 1.09 (0.98, 1.20)
Region P  0.2229
Scotland & North of England 741 632 35.66 1.19 - -
Midlands & Wales 475 408 35.09 2.19 0.96 (0.87, 1.05)
East of England & South of England 907 859 39.10 1.32 1.04 (0.96, 1.13)
Relationship and children
Relationship status P  0.9109
Married / civil partnership / cohabiting 1203 1234 35.50 0.92 - -
Steady relationship, not living together 257 196 42.54 2.39 1.01 (0.89, 1.14)
Not in a steady relationship 646 449 39.75 2.08 1.02 (0.94, 1.10)
Any natural children P  0.6694
No 597 520 43.25 2.25 - -
Yes 1497 1336 34.67 0.78 1.02 (0.93, 1.12)
Lives with a child (aged 18y) P  0.5441
No 1409 1179 35.80 1.15 - -
Yes 711 717 39.09 1.29 1.03 (0.94, 1.12)
BMI
BMI$ P  0.7452
Normal (BMI 18.5–25 kg/m2) 965 870 39.39 1.23 - -
Overweight (BMI 25–30 kg/m2) 586 504 34.82 1.37 0.97 (0.89, 0.94)
Obese (BMI 30 kg/m2) 428 355 35.13 1.53 0.97 (0.90, 0.94)
General health and function
Self-reported general health P  0.3880
Very good/good 1753 1560 37.91 0.98 - -
Fair/bad/very bad 370 339 33.33 1.65 0.96 (0.88–1.05)
Longstanding illness or disability P  0.8803
No 1360 1281 38.21 1.11 - -
Yes 763 618 34.77 1.37 1.01 (0.92–1.10)
Difficulty walking up stairs because
of a health problem
P  0.4682
No difficulty 1787 1598 38.11 0.95 - -
Some difficulty 241 221 32.92 2.62 0.99 (0.87, 1.13)
Much difficulty or unable 95 80 28.4 2.79 0.87 (0.69, 1.09)
Number of comorbid conditions* P  0.5587
0 1177 1101 39.52 1.22 - -
1 546 474 35.01 1.33 0.99 (0.91, 1.08)
2 400 324 31.91 2.00 0.93 (0.82, 1.06)
Lifestyle
Current smoker P  0.0165
No 1714 1548 35.88 0.82 - -
Yes 409 351 42.44 2.45 1.11 (1.02, 1.22)
Average alcohol consumption per
week
P  0.3272
None 640 606 36.04 1.57 - -
Not more than recommended 1280 1113 37.97 1.13 1.06 (0.98, 1.16)
(Continued )
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Table 2. Continued
Denominators
(n) (unwt, wt)
mean sal-T
(pmol/liter) (SE.)
age-
adjusted
Ratios# (95% CI)
More than recommended 198 175 35.23 2.08 1.02 (0.91, 1.15)
Taken non-prescribed drugs, past
year
P  0.3064
No 1970 1746 36.68 0.90 - -
Yes 115 106 46.44 4.01 1.09 (0.93, 1.28)
unwt  unweighted; wt  weighted
#Ratio of geometric means, obtained from exponentiated age-adjusted linear regression coefficients of log-transformed data for women. Adjusted
for age and age-squared to account for non-linear relationship between testosterone and age
*Measure of comorbidity includes arthritis, heart attack, coronary heart disease, angina, other forms of heart disease, hypertension, stroke,
diabetes, broken hip or pelvis bone or hip replacement ever, backache lasting longer than 3 months, any other muscle or bone disease lasting
longer than 3 months, treatment for depression, treatment for cancer, and treatment for any thyroid condition in the past year.
$Those with BMI18.5 have been excluded from analysis due insufficient numbers to analyse this group separately
Table 3. Adjusted associations between demographic and health factors and salivary Testosterone (sal-T): MEN
Denominators (n)
(unwt, wt)
age-adjusted
coefficients (95% CI)
Domain
1 adjusted
coefficients (95% CI)
Domain
2 adjusted
coefficients (95% CI)
Domain
3 adjusted
coefficients (95% CI)
Domain
4 adjusted
coefficients (95% CI)
Age, season, region
Age P  0.0001 P  0.0001 P  0.0001 P  0.0001 P  0.0001
18–24 186 242 - - - - - - - - - -
25–34 245 328 51.19 (-74.44, 27.94) 52.08 (-75.40, 28.75) 41.05 (-65.54, 16.56) 33.70 (-58.31, 9.09) 31.90 (-56.44, 7.35)
35–44 236 363 81.65 (-105.90, 57.41) 81.66 (-105.55, 57.78) 69.74 (-94.08, 45.39) 62.79 (-86.52, 39.07) 60.66 (-84.61, 36.71)
45–54 297 388 110.08 (-130.78, 89.37) 109.69 (-130.35, 89.03) 97.21 (-118.62, 75.81) 82.80 (-104.26, 61.35) 79.74 (-101.33, 58 .16)
55–64 330 334 141.18 (-160.84, 121.52) 140.78 (-160.37, 121.18) 126.87 (-147.78, 105.96) 111.77 (-132.95, 90.59) 107.91 (-128.99, 86.82)
65–74 305 231 164.09 (-183.51, 144.68) 163.73 (-183.04, 144.42) 149.80 (-170.91, 128.70) 134.69 (-155.81, 113.56) 130.48 (-151.83, 109.13)
Season P  0.0360 P  0.0360 P  0.0256 P  0.0368 P  0.0294
winter 400 500 - - - - - - - - - -
spring 464 521 5.75 (-20.90, 9.40) 5.75 (-20.90, 9.40) 6.57 (-21.79, 8.66) 1.93 (-15.68, 11.81) 2.00 (-15.76, 11.75)
summer 421 457 20.73 (-36.74, 4.72) 20.73 (-36.74, 4.72) 21.48 (-37.47, 5.49) 16.41 (-30.21, 2.61) 16.76 (-30.56, 2.96)
autumn 314 408 2.95 (-19.42, 13.52) 2.95 (-19.42, 13.52) 2.90 (-19.44, 13.64) 1.24 (-13.03, 15.52) 1.46 (-12.79, 15.71)
Relationship and children
Relationship status P  0.0103 P  0.0073 P  0.0185 P  0.0110
Married/civil partnership/cohabiting 928 1277 - - - - - - - -
Steady relationship, not living
together
187 179 14.62 (-1.89, 31.13) 16.02 (-0.55, 32.58) 11.18 (-4.54, 26.91) 11.68 (-4.07, 27.42)
Not in a steady relationship 459 405 20.12 (6.41, 33.82) 20.50 (6.85, 34.15) 18.52 (5.13, 31.91) 20.10 (6.50, 33.70)
Any natural children P  0.374
No 642 736 - -
Yes 928 1104 5.80 (-18.61, 7.00)
Lives with a child (aged
18y)
P  0.7611
No 1281 1342 - -
Yes 318 544 2.17 (-16.21, 11.86)
BMI P  0.0001 P  0.0001
BMI$ P  0.0001
Normal (BMI 18.5–25
kg/m2)
599 723 - - - - - -
Overweight (BMI 25–30
kg/m2)
612 715 23.63 (-34.81, 12.46) 22.40 (-33.63, 11.17) 22.33 (-33.56, 11.11)
Obese (BMI 30
kg/m2)
334 365 51.26 (-64.64, 37.88) 49.69 (-62.84, 36.54) 47.59 (-61.22, 33.96)
General health and function
Self-reported general health P  0.0054 P  0.048
Very good/good 1253 1510 - - - - - -
Fair/bad/very bad 346 375 16.14 (-27.50, 4.78) 11.39 (-22.69, 0.10)
Longstanding illness or
disability
P  0.0131
No 977 1251 - -
Yes 621 634 13.36 (-23.91, 2.81)
Difficulty walking up
stairs because of a
health problem
P  0.0499
No difficulty 1369 1643 - -
Some difficulty 166 177 8.31 (-23.34, 6.71)
Much difficulty or
unable
64 66 23.74 (-44.08, 3.41)
Number of comorbid
conditions*
P  0.0073
0 913 1169 - -
1 397 435 11.10 (-24.18, 1.98)
2 289 282 21.57 (-35.10, 8.04)
unwt  unweighted; wt  weighted
Variables were grouped into a hierarchy of ’domains’ as follows: 1. Age, season, region; 2. Relationship status and family; 3. BMI; 4. General
health and function. ’Lifestyle’ factors (smoking, drinking, drug use’ were not included in the adjusted analysis given lack of associations seen in
age-adjusted analysis.
The variables were entered in these groups in order, and including any variables found to be significant from previous domains, into forwards
stepwise linear (interval) regression models to generate adjusted coefficients. The significance criteria for retention in the model was P  0.1.
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season, and relationship status, in which self-reported
general health was found to be more strongly associated
with Sal-T (-19.01 (-30.48 to –7.54) P  .001; data not
shown).
Specific health conditions (Table 4)
Cardiovascular disease (including hypertension) was
reportedby19%ofmen inour sample, andwasassociated
with lower mean Sal-T in men, independently of age
(-18.06 (-29.43 to –6.68)). There was also an association
with currently taking medication for depression (-24.56
(-48.33 to –0.79), reported by 4% of men), but not with
current depressive symptoms (10%
of men screened positive for depres-
sive symptoms in the past two
weeks). After adjustment for age,
there was at best weak evidenceof an
association with self-reported doc-
tor-diagnosed diabetes (reported by
6% of men in our sample). Further
adjustment for season, relationship
status, and BMI attenuated the asso-
ciation with cardiovascular disease
(-8.98 (-20.27 to 2.31); P  .119)
and diabetes (-5.51 (-23.1–12.1);
P .540) but strengthened the asso-
ciation with depression medication
(-28.02 (-51.64 to –4.40);P .020).
There was no evidence of associa-
tions between Sal-T and any of these
conditions among women.
Discussion
Summary of findings and
comparison with other studies
This study is the first to show as-
sociations between salivary testos-
terone (Sal-T) and health in a large
national probability-sample survey
of men and women, across a wide
age range. In men, we found signifi-
cant age-independent associations
between lower Sal-T and higher
BMI, poorer self-reported general
health, mobility problems, long-
standing illness, and comorbid con-
ditions (cardiovascular disease,
treatment for depression). The asso-
ciation between Sal-T and self-re-
ported general health in men was at-
tenuated after adjustment for BMI,
suggesting that the relationship is at least partly explained
by obesity. We found no associations between Sal-T and
health factors in women, except smoking, with higher
Sal-T among women who smoked.
The present finding of an age-related decline in Sal-T
that persisted even after adjusting for health and demo-
graphic factors is consistent with previous serum studies
that found not only serum total-T, but also serum free-T,
declined across an age range inwomen (9) andmen similar
to Natsal-3 (25). Others, however, have argued that the
age-related decline in serum total-T may entirely be ex-
Figure 1. Mean (95% Confidence Interval) Sal-T (pmol/l) by age group and BMI
Note: figures for men and women have different scales a) Men b) Women
8 Salivary testosterone and health in British men and women J Clin Endocrinol Metab
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 19 September 2016. at 07:07 For personal use only. No other uses without permission. . All rights reserved.
plained by declining health (6). This inconsistency may
partly be explained by the age-related increase in sex hor-
mone binding globulin (SHBG) which attenuates the age
trend in total serum-T, but not serum free-T (5) or Sal-T.
Our findings of associationswith health-related factors
in men are largely consistent with evidence from serum
studies. There is a large body of evidence that, in men,
obesity is strongly associated with lower serum-T, inde-
pendently of age (3). Associations have also been reported
between lower serum-T and insulin resistance and diabe-
tes, preclinical indicators for cardiovascular disease
(CVD), cardiovascular events, phys-
ical frailty and increased mortality
(3, 5, 26, 27). Cross-sectional data
cannot shed light on the direction of
these relationships but longitudinal
studies have found that obesity leads
to decreases in testosterone, and
weight loss increases testosterone
levels in obese men, (28) although
there is also evidence of bidirectional
associations (3). Longitudinal se-
rum-T studies have shown that low
testosteroneprecedes cardiovascular
events (26). The mechanisms of this
association are unclear and may in-
volve low testosterone affecting sev-
eral cardiovascular risk factors, cen-
tral adiposity and inflammation
(29). Unlike most serum-T studies
we did not find an age-adjusted as-
sociation with self-reported diabetes
formenwith P .0932 indicating at
bestweak evidenceof anassociation,
which did not persist after adjusting
for other confounding factors in-
cluding BMI. Although prevalence
of diabetes in our samplewas similar
to national estimates (30), the abso-
lute number of men with diabetes in
our sample was relatively small thus
limiting our power to detect an as-
sociation. However other research
has shown that the apparent associ-
ation between diabetes and low se-
rum total-T, but not free-T, may be
confounded by obesity and low
SHBG,which is in linewith our find-
ings (31). We found no association
with current depressive symptoms
but did observe an association with
treatment for depression. Little re-
search exists on the effects of antide-
pressants on the hypothalamic-pituitary-gonadal axis, al-
thoughone studyhas foundhigherSal-T levels amongmen
andwomen using Selective Serotonin Reuptake Inhibitors
(SSRIs), which contrasts with our results (32).
We examined associations between Sal-T and several
demographic factors in order to address potential con-
founding of the associationswith health. A previous study
found ethnic variation in testosterone levels, however we
were unable to examine this due to small numbers of par-
ticipants in ethnic minority groups. The findings of this
Figure 2. Mean (95% Confidence Interval) Sal-T (pmol/l) by age group and self-
reported general health status Note: figures for men and women have different scales
a) Men b) Women
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study only partly concur with those from (generally
smaller) studies which have reported lower testosterone
among men and women in established relationships (33)
and parents, especially those actively involved in childcare
(34, 35). We found associations with relationship status
for men only, and no associations with parenthood for
either men or women, however our measures of parent-
hood capture a broad range of circumstances regarding
children’s age and parents’ involvement in child-rearing,
which may explain this apparent discrepancy.
We found no association between Sal-T and smoking,
alcohol consumption, or drug use in men. Previous se-
rum-T studies inmen have generally, although not always
consistently, shown smoking to be associated with in-
creased total-T, and studies of the associationswith free-T
have yieldedmixed results (36). Smoking, via direct effects
on liver function, increases SHBG levels, which may ex-
plain why total-Tis increased in smokers yet in our study
we did not find an associationwith Sal-T inmen (36). The
evidence regardingwhether testosterone is associatedwith
alcohol consumption is alsomixed, (27, 37) and few stud-
ies have examined associations with other drugs.
Previous research about the health correlates of testos-
terone in women has not only yielded inconsistent find-
ings, but has largely been carried out within narrow age
ranges, and using suboptimal measures of testosterone
(14).We found no evidence of associations between Sal-T
and general health indicators, or specific conditions or
medications in women.We did find a positive association
with smoking, which is consistent with other studies (11,
38).We also found lower mean Sal-T among womenwho
had taken hormonal contraception, which can be ex-
plainedby the combined effects of a direct inhibitory effect
on ovarian androgen synthesis, an increase in SHBG con-
centration, and an inhibitory effect on adrenal androgen
production (39). The association between Sal-T and
smoking in women became nonsignificant after excluding
womenwho had taken hormonal contraception, however
the effect estimate was similar, so it is likely that this
change in statistical significant is due to the reduction in
sample size and resulting increase in confidence intervals,
rather than a true difference between these groups of
women.
Our findings regarding the different relationship with
health and obesity for men and women may relate to the
different sites of production and mechanisms of regula-
tion. Among women, testosterone is produced from the
adrenal glands, regulated byACTH, aswell as the ovaries,
regulated by gonadotrophins, and there are menstrual cy-
clical fluctuations of ovarian steroids, whereas inmen tes-
tosterone is produced predominantly from the testes with
only a very minor contribution from the adrenals. The
mechanisms underlying the relationship between obesity
and low testosterone in men remain unclear, although the
potential importance of circulating inflammatory cyto-
kines fromvisceral adipose depots is gaining credence (40,
41).
Strengths and limitations
A key strength of this study is the highly sensitive and
specific Sal-T assay, enabling accurate measurement in
women as well as men - although there is some systematic
positive bias due to salivary protein binding among
women (19) - and permittingmeasurement of testosterone
Table 4. Associations between reporting specific health conditions and medical treatmentsand salivary
Testosterone (Sal-T) by gender
Men Women
Denominators (n) unwt, wt
mean sal-T
(pmol/liter) (SE.)
age-adjusted
coefficients (95% CI)
Denominators (n)
unwt, wt
mean sal-T
(pmol/liter) (SE.)
age-adjusted
ratios# (95% CI)
All 1599 1886 223.49 3.33 2123 1899 37.09 0.86
Any cardiac or
vascular disease or
hypertension
P  0.0019 P  0.6863
no 1257 1548 235.47 3.75 - - 1789 1625 37.99 0.95 1.00 -
yes 342 338 168.6 4.92 18.06 (-29.43, 6.68) 334 275 31.79 1.71 0.98 (0.88, 1.09)
Diabetes P  0.0932 P  0.4689
no 1482 1769 227.47 3.4 - - 2036 1828 37.34 0.87 1.00 -
yes 117 116 162.98 8.82 15.55 (-33.71, 2.61) 87 71 30.67 2.54 0.93 (0.77, 1.13)
Currently taking
medication for
depression
P  0.0428 P  0.5670
no 1513 1810 224.79 3.42 - - 1930 1737 37.29 0.92 1.00 -
yes 86 75 192.34 11.61 24.56 (-48.33, 0.79) 193 163 34.99 2.11 0.97 (0.86, 1.09)
Depressive symptoms P  0.7057 P  0.7079
no 1386 1644 223.84 3.41 - - 1864 1646 37.13 0.81 1.00 -
yes 176 186 228.68 11.25 4.00 (-24.77, 16.77) 222 206 38.04 3.74 0.97 (0.85, 1.12)
unwt  unweighted; wt  weighted
Participants were asked whether they had often been bothered by feeling down, depressed, or hopeless in hte past 2 weeks, and whether they
had often been bothered by little interest or pleasure in doing things in the past 2 weeks, using a validated two-question patient health
questionnaire (PHQ-2).
#Ratio of geometric means, obtained from exponentiated age-adjusted linear regression coefficients of log-transformed data for women
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on a large-scale probability-sample survey across a wide
age range. Although less invasive than serum, large-scale
home-based collection of saliva has presented a number of
challenges including: coping with the diurnal variation in
testosterone levels, preventing contamination, ensuring
prompt receipt at the laboratory before deterioration, and
minimizing nonresponse bias. Considerable attentionwas
paid to the development of protocols for sample collec-
tion, with extensive validation and piloting, (21) yet al-
though 71.0%of participants agreed to provide a sample,
useable samples were received from only 45.0% of those
invited, highlighting the challenge of obtaining self-col-
lected and self-posted samples. This response rate is sim-
ilar to community-based serum testosterone studies, (42,
43) and the response rate to the survey overall was similar
to othermajor British social surveys.However, therewere
some systematic differences in the characteristics of those
who returned a valid saliva sample, for example older
participantsweremore likely to give a sample, therefore to
minimize potential nonresponse bias, both to the survey
and to the saliva sample, we applied statistical weights
during analysis (21).
The health data collected were self-reported and are
therefore reliant on knowledge of conditions and medi-
cations, and accurate reporting. This may particularly af-
fect BMI based on self-reported height andweight, as peo-
ple tend to underestimate weight and overestimate height.
However, previous studies have shown self-reported
height and weight to be sufficient for examining associa-
tions in epidemiological studies (44). As a sexual health
survey, only a limited number of questions about general
health could be asked, thereforewewere unable to look at
associations with some factors that may have been of in-
terest such as frailty, osteoporosis, or sleep disturbance.
We were also unable to measure preclinical disease
indicators.
Only one sample was collected from each participant
and so we were unable to take into account intra-individ-
ual variation in testosterone levels, which may be partic-
ularly relevant for premenopausal women as testosterone
varies throughout the menstrual cycle (45). However,
some have argued that it is unnecessary to control for
menstrual variation, given the relatively small effects com-
pared with, for example, diurnal variation or individual
differences (45). This is consistent with our earlier vali-
dation work in which did not find significant within-in-
dividual differences when samples were taken at weekly
and monthly intervals (17). A small number of men and
women (n  20 and n  37 respectively) included in our
analysis reported receiving cancer treatment in the past
year, and as the nature of the cancer or treatment was
unknown, this could have affected testosterone levels for
some.However, given the small numbers this is unlikely to
have affected our findings overall.
Implications for clinical research, policy, and
further research need
The findings presented in this paper provide crucial
background for future research into the relationship be-
tween Sal-T and sexual function and sexual behavior, as
well as being important in their own right for understand-
ing associations between Sal-T and health factors. Our
findings are broadly consistent with previous research us-
ing serum, andwhere differences exist it is not always clear
whether these are due to differences in the measure used
(serum total-T, free-T, or Sal-T), or due to other differ-
ences in the study population and design. Further obser-
vational research using reliable saliva T measurements
linked to a broader range of clinical correlates would
strengthen the evidence base in this respect.
There are concerns about inappropriatemarketing and
use of testosterone replacement therapy (TRT) for men,
particularly in the USA (7). Our cross-sectional finding of
lower Sal-T amongmenwith poorer health does not imply
causality, nor indicate treatment. Although longitudinal
research has shown that low testosterone precedes poor
health outcomes (26) the benefits of TRT in the general
population remain unclear. Further research is needed be-
fore conclusions canbe reached regarding thenatureof the
relationship between testosterone and ill-health, and the
risks and benefits of intervention.
Our finding of an independent age-related decline in
Sal-T suggests that reproductive senescence in men, as in
women, is not solely the consequence of poor health. The
clinical significance of this merits further investigation us-
ing Sal-T as well as serum-T measurements. The applica-
tion of Sal-Tmeasurement in future research shouldmake
a significant contribution towards clarifying the role of
low testosterone in health and ageing in men and women.
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